FAST NEWS: Everest Medicines loss widens on drug commercialization
The Latest: Everest Medicines Ltd. (1952.HK) announced Tuesday its revenue for the first half of this year surged about 33 times to 302 million yuan ($42.3 million), while its net loss jumped 49%…
FAST NEWS: Everest Medicines gets new drug license from Kezar Life
The latest: Everest Medicines Ltd. (1952.HK) announced Thursday that it has received an exclusive license from Kezar Life Sciences (KZR.US) to develop, manufacture and commercialize Zetomipzomib, a treatment for autoimmune diseases,…
FAST NEWS: Everest Medicines Plunges After Terminating Breast Cancer Drug Deal
The latest: Everest Medicines Ltd. (1952.HK) announced Tuesday that it is terminating its agreement to develop Gilead Science’s (GILD.US) Sacituzumab Govitecan breast cancer drug for the China market. Looking up:…
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK -
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Innogen Pharma jostles for a slice of the weight-loss market
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
